Truist Financial Corp Cel Sci Corp Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$8.68 - $27.49 $467,209 - $1.48 Million	-53,826 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $554,100 - $1.28 Million	-46,175 Reduced 46.17%	53,826 $819,000
Q4 2020 Nov 19, 2021	SELL	$11.05 - $16.62 $27,625 - $41,550	-2,500 Reduced 2.44%	100,001 $1.17 Million
Q4 2020 Feb 18, 2021	SELL	$11.05 - $16.62 $184,137 - $276,955	-16,664 Reduced 13.98%	102,501 $1.2 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $17.05 $7 - $17	1 Added 0.0%	119,165 $1.38 Million
Q4 2019 Feb 14, 2020	BUY	$6.71 - $9.55 $799,590 - $1.14 Million	119,164 New	119,164 $1.09 Million

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.